Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung ca

用于靶向肺癌的非肽大环组蛋白脱乙酰酶 (HDAC) 抑制剂

• 批准号: 7785028
• 负责人: Adegboyega Oyelere
• 金额: $ 29.55万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-25 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7785028
• 关键词: A549; Adverse effects; Antineoplastic Agents; Azithromycin; Behavior; Binding; Biochemical; Biological Assay; Cancer Etiology; Cancer Model; Cancer cell line; Cell Line; Cells; Cervix Uteri; Cessation of life; Chromatin; Collection; Cutaneous; Cyclic Peptides; DNA; Data; Deacetylase; Deacetylation; Docking; Drug Kinetics; Drug or chemical Tissue Distribution; Enzymatic Biochemistry; Enzymes; Epithelial Cells; Excision; FDA approved; Family; Fibroblasts; Genes; Goals; Gonadotropin-Releasing Hormone Receptor; HDAC7 histone deacetylase; Health; Histone Deacetylase; Histone Deacetylase Inhibitor; Histone deacetylase inhibition; Histones; Human; In Vitro; Lead; Literature; Lung; Lysine; Macrolide Antibiotics; Macrolides; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Mammary gland; Methods; Molecular; Mus; Organ; Organic Chemistry; Patients; Pattern; Peptides; Protein Acetylation; Protein Isoforms; Reaction; Research; Research Design; Role; Series; Side; Skeleton; Structure; Survival Rate; T-Cell Lymphoma; Therapeutic; Therapeutic Index; Tissues; Tonsil; Vertebral column; Vorinostat; Xenograft Model; base; cancer therapy; cell transformation; cell type; chemotherapeutic agent; computational chemistry; design; gene repression; hydroxamate; improved; in vivo; inhibitor/antagonist; insight; lung small cell carcinoma; male; novel; novel therapeutics; outcome forecast; pharmacophore; pre-clinical; public health relevance; research clinical testing; research study; spelling; tool; tumor

DESCRIPTION (provided by applicant): We seek to identify novel nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors as a new class of anticancer agents. HDAC inhibitors hold great promise in cancer therapy due to their demonstrated ability to arrest proliferation of nearly all transformed cell types. However, most of these agents are non-selective inhibitors of all HDAC isoforms; and a large number of the identified HDAC inhibitors have not progressed beyond preclinical characterizations. Our hypothesis in this proposal is that substitution of the peptide moiety of a prototypical cyclic- peptide HDAC inhibitor with specific non-peptidyl macrocyclic surrogates will generate a new class of potent HDAC inhibitors with improved therapeutic index. These compounds are anticipated to also possess targeted anti-cancer activity due to selective tissue distribution conferred by the appended macrocyclic moiety. In Preliminary Results a class of macrocyclic hydroxamates has been identified. The goal of this application is to study the molecular mechanisms underlying the in vitro anti-HDAC and anti-tumor activities of these compounds. Aim 1 is to develop novel nonpeptide macrocyclic HDAC inhibitors. The first step here is to broaden our design approach to include other structurally similar macrocyclic templates in order to create a tool set upon which subsequent structure activity relation (SAR) studies will be based. To guide this effort, we will use molecular docking (AutoDock) to investigate the SAR of the combination of these macrocyclic templates with key HDAC inhibitor pharmacophores. Aim 2 is to characterize the structural and biochemical requirements for in vitro and whole cell HDAC inhibition. Toward this end, we will profile the anti-HDAC activity of compounds obtained from the priority list generated by the docking experiments using both in vitro HDAC inhibition assay and whole cell activity in human lung cancer cell lines. Moreover, we will evaluate the whole cell mechanism of our potent inhibitors based on intracellular status of p21WAF1/CIP1 and HDAC7 genes, and histone protein acetylation patterns. Our Aim 3 is to investigate the organ distribution and in vivo efficacy of lead compounds in mice. We will first study compound organ distribution behavior in healthy male Balb/c mice. Compounds displaying lung selective accumulation with good pharmacokinetic parameters will then be advanced to in vivo efficacy studies in Balb/c (nu/nu) mice bearing xenograft models of specific lung cancers. In the longer term, we will identify series of novel HDAC inhibitors that will be advanced to further preclinical/clinical evaluations. Additionally, the proposed studies will yield new insights on the roles of HDACs in the etiology of cancer. PUBLIC HEALTH RELEVANCE: Lung cancer is the leading cause of cancer deaths in the US. Outlined in this proposal is a method that will enable identification of new classes of chemotherapeutic agents that possess lung- selective anti-cancer activity for targeted lung cancer therapy applications. Our proposed approach is expected to lead to chemotherapeutic agents with superior therapeutic indices and will significantly impact patient survival prognosis and positively contribute to human health management.

描述（由申请人提供）：我们试图鉴定新型非肽大环组蛋白脱乙酰酶（HDAC）抑制剂作为一类新的抗癌药物。HDAC抑制剂在癌症治疗中具有很大的前景，因为它们被证明能够阻止几乎所有转化细胞类型的增殖。然而，这些药物中的大多数是所有HDAC亚型的非选择性抑制剂;并且大量已鉴定的HDAC抑制剂尚未进展超过临床前表征。我们在该提议中的假设是，用特异性非肽基大环替代物取代原型环肽HDAC抑制剂的肽部分将产生一类具有改善的治疗指数的新的有效HDAC抑制剂。由于附加的大环部分赋予的选择性组织分布，预期这些化合物还具有靶向抗癌活性。在初步结果中，已经鉴定了一类大环异羟肟酸盐。本申请的目的是研究这些化合物的体外抗HDAC和抗肿瘤活性的分子机制。目的1：开发新型非肽类大环HDAC抑制剂。这里的第一步是扩大我们的设计方法，包括其他结构相似的大环模板，以创建一个工具集，随后的结构活性关系（SAR）的研究将基于。为了指导这项工作，我们将使用分子对接（AutoDock）来研究这些大环模板与关键HDAC抑制剂药效团组合的SAR。目的2是表征体外和全细胞HDAC抑制的结构和生化要求。为此，我们将使用体外HDAC抑制测定和人肺癌细胞系中的全细胞活性来分析从通过对接实验产生的优先级列表获得的化合物的抗HDAC活性。此外，我们将根据p21 WAF 1/CIP 1和HDAC 7基因的细胞内状态以及组蛋白乙酰化模式来评估我们的强效抑制剂的全细胞机制。我们的目的3是研究铅化合物在小鼠中的器官分布和体内功效。我们将首先研究健康雄性Balb/c小鼠的复合器官分布行为。然后将显示具有良好药代动力学参数的肺选择性蓄积的化合物推进到携带特定肺癌异种移植模型的Balb/c（nu/nu）小鼠中的体内功效研究。从长远来看，我们将确定一系列新的HDAC抑制剂，这些抑制剂将进一步进行临床前/临床评价。此外，拟议的研究将对HDAC在癌症病因学中的作用产生新的见解。公共卫生相关性：肺癌是美国癌症死亡的主要原因。本提案中概述了一种方法，该方法将能够识别具有肺选择性抗癌活性的新型化疗药物，用于靶向肺癌治疗应用。我们提出的方法有望导致具有上级治疗指数的化疗药物，并将显著影响患者的生存预后，并对人类健康管理做出积极贡献。